Qi Guoyan, Gu Shanshan, Liu Peng, Yang Hongxia, Dong Huimin
First Hospital of Shijiazhuang, Center of Treatment of Myasthenia Gravis Hebei Province, China.
Int J Clin Exp Med. 2015 Oct 15;8(10):19044-50. eCollection 2015.
Myasthenia gravis (MG) is a kind of autoimmune disease induced by transferring dysfunction of neuromuscular junction. In the present study, we developed an integrated therapy combined with traditional Chinese medicine and immuno suppressive agents to seek for an effective treatment of MG. 220 MG patients were randomly divided into two groups with different therapies. Plasma levels of acetylcholine receptors antibodies (AchRAb) and CD4(+)CD25(+) regulatory T cells (CD4(+)CD25(+)Treg) were conducted through ELISA and flow cytometry. The amount of AchRAb (8.52±0.96 vs. 5.22±0.46) and CD4(+)CD25(+)Treg (1.94±1.21 vs. 3.21±0.96) in Group A receiving integrated therapy were significantly improved compared with Group B; the clinical performance of group treated with the integrated therapy was also much better. The integrated therapy in the present study could significantly improve the condition of MG with high recovery rate and low recurrence rate, which can be employed in future clinical treatment of MG.
重症肌无力（MG）是一种由神经肌肉接头传递功能障碍引起的自身免疫性疾病。在本研究中，我们开发了一种结合中药和免疫抑制剂的综合疗法，以寻求一种有效的MG治疗方法。220例MG患者被随机分为两组接受不同治疗。通过酶联免疫吸附测定（ELISA）和流式细胞术检测乙酰胆碱受体抗体（AchRAb）和CD4(+)CD25(+)调节性T细胞（CD4(+)CD25(+)Treg）的血浆水平。接受综合疗法的A组患者的AchRAb量（8.52±0.96对5.22±0.46）和CD4(+)CD25(+)Treg量（1.94±1.21对3.21±0.96）与B组相比有显著改善；接受综合疗法治疗组的临床表现也更好。本研究中的综合疗法可显著改善MG病情，恢复率高且复发率低，可用于未来MG的临床治疗。
